Jan Lerut

Jan Lerut

Auto-generated profile, based on publicly available information

Jan Lerut

Institute for Experimental and Clinical Research (IREC), Université catholique Louvain (UCL), Avenue Hippocrate 56, 1200 Woluwe Saint Pierre, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in The Lancet Oncology
Verified
Journal Article
Closed access
VMVincenzo Mazzaferro
Vincenzo Mazzaferro
JLJosep M Llovet
Josep M Llovet
RMRosalba Miceli
Rosalba Miceli
SBSherrie Bhoori
Sherrie Bhoori
MSMarcello Schiavo
Marcello Schiavo
PMPietro Majno
Pietro Majno

1 September 2012 in Journal of Hepatology
Verified
Journal Article
Open access
RARené Adam
René Adam
VKVincent Karam
Vincent Karam
VDValérie Delvart
Valérie Delvart
JOJohn O’grady
John O’grady
DMDarius Mirza
Darius Mirza
ABAndrew Burroughs
Andrew Burroughs

1 May 2004 in Annals of Surgery
Verified
Journal Article
Closed access
ADAchilles A. Demetriou
Achilles A. Demetriou
RBRobert S. Brown
Robert S. Brown
RBRonald W. Busuttil
Ronald W. Busuttil
JFJeffrey Fair
Jeffrey Fair
BMBrendan M. McGuire
Brendan M. McGuire
BSBarry A. Solomon
Barry A. Solomon
The HepatAssist liver support system is an extracorporeal porcine hepatocyte-based bioartificial liver (BAL). The safety and efficacy of the BAL were evaluated in a prospective, randomized, controlled, multicenter trial in patients with severe acute liver failure. In experimental animals with acute liver failure, we demonstrated beneficial effects of the BAL. Similarly, Phase I trials of the BAL in acute liver failure patients yielded promising results. A total of 171 patients (86 control and 85 BAL) were enrolled. Patients with fulminant/subfulminant hepatic failure and primary nonfunction following liver transplantation were included. Data were analyzed with and without accounting for the following confounding factors: liver transplantation, time to transplant, disease etiology, disease severity, and treatment site. For the entire patient population, survival at 30 days was 71% for BAL versus 62% for control (P = 0.26). After exclusion of primary nonfunction patients, survival was 73% for BAL versus 59% for control (n = 147; P = 0.12). When survival was analyzed accounting for confounding factors, in the entire patient population, there was no difference between the 2 groups (risk ratio = 0.67; P = 0.13). However, survival in fulminant/subfulminant hepatic failure patients was significantly higher in the BAL compared with the control group (risk ratio = 0.56; P = 0.048). This is the first prospective, randomized, controlled trial of an extracorporeal liver support system, demonstrating safety and improved survival in patients with fulminant/subfulminant hepatic failure.

1 March 2002 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
JVJean-Nicolas Vauthey
Jean-Nicolas Vauthey
EAEddie K. Abdalla
Eddie K. Abdalla
DDDorota A. Doherty
Dorota A. Doherty
PGPhilippe Gertsch
Philippe Gertsch
MFMarc J. Fenstermacher
Marc J. Fenstermacher
ADAlban Denys
Alban Denys
Computed tomography (CT) is used increasingly to measure liver volume in patients undergoing evaluation for transplantation or resection. This study is designed to determine a formula predicting total liver volume (TLV) based on body surface area (BSA) or body weight in Western adults. TLV was measured in 292 patients from four Western centers. Liver volumes were calculated from helical computed tomographic scans obtained for conditions unrelated to the hepatobiliary system. BSA was calculated based on height and weight. Each center used a different established method of three-dimensional volume reconstruction. Using regression analysis, measurements were compared, and formulas correlating BSA or body weight to TLV were established. A linear regression formula to estimate TLV based on BSA was obtained: TLV = −794.41 + 1,267.28 × BSA (square meters; r 2 = 0.46; P < .0001). A formula based on patient weight also was derived: TLV = 191.80 + 18.51 × weight (kilograms; r 2 = 0.49; P < .0001). The newly derived TLV formula based on BSA was compared with previously reported formulas. The application of a formula obtained from healthy Japanese individuals underestimated TLV. Two formulas derived from autopsy data for Western populations were similar to the newly derived BSA formula, with a slight overestimation of TLV. In conclusion, hepatic three-dimensional volume reconstruction based on helical CT predicts TLV based on BSA or body weight. The new formulas derived from this correlation should contribute to the estimation of TLV before liver transplantation or major hepatic resection.

1 December 2003 in Liver Transplantation
Verified
Journal Article
Closed access
RARené Adam
René Adam
PMPaul McMaster
Paul McMaster
JOJohn G. O’grady
John G. O’grady
DCDenis Castaing
Denis Castaing
JKJurgen L. Klempnauer
Jurgen L. Klempnauer
EGEnrique Moreno Gonzalez
Enrique Moreno Gonzalez
The European Liver Transplant Registry (ELTR) currently allows for the analysis of 44,286 liver transplantations (LTs) performed on 39,196 patients in a 13-year period. After an exponential increase, the number of LTs is plateauing due to a lack of organs. To cope with this, alternatives to cadaveric LT, such as split LT, domino LT, or living-related LT (LRLT) are being used increasingly. They now account for 11% of all procedures. One of the most important findings in the evolution of LT is the considerable improvement of results along time with, for the mean time, a one-year survival of 83%, all indications confounded. The improvement is particularly significant for cancers. This improvement is mainly represented by hepatocellular carcinoma, with a gain of 17% for 5-year survival rate from 1990 to 2000. Increasingly, older donors are used to augment the donor pool and older recipients are transplanted due to improved results and a better selection of patients. More than two thirds of deaths and three quarters of retransplantations occurred within the first year of transplantation. Retransplantation is associated with much less optimal results than first LT. One of the prominent features of recent years is the development of LRLT. LRLT is now performed by almost half of the European centers. As with split LT or domino LT, LRLT aims to provide more patients to be transplanted. Special attention is paid to reducing the risk for the donor, which is now estimated to be 0.5% mortality and 21% postoperative morbidity.

18 January 2007 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MMM. Martínez-Llordella
M. Martínez-Llordella
IPI Puig-Pey
I Puig-Pey
GOG. Orlando
G. Orlando
MRM. Ramoni
M. Ramoni
GTG. Tisone
G. Tisone
ASA. Sánchez-Fueyo
A. Sánchez-Fueyo
Immunosuppressive drugs can be completely withdrawn in up to 20% of liver transplant recipients, commonly referred to as ‘operationally’ tolerant. Immune characterization of these patients, however, has not been performed in detail, and we lack tests capable of identifying tolerant patients among recipients receiving maintenance immunosuppression. In the current study we have analyzed a variety of biological traits in peripheral blood of operationally tolerant liver recipients in an attempt to define a multiparameter ‘fingerprint’ of tolerance. Thus, we have performed peripheral blood gene expression profiling and extensive blood cell immunophenotyping on 16 operationally tolerant liver recipients, 16 recipients requiring on-going immunosuppressive therapy, and 10 healthy individuals. Microarray profiling identified a gene expression signature that could discriminate tolerant recipients from immunosuppression-dependent patients with high accuracy. This signature included genes encoding for γδ T-cell and NK receptors, and for proteins involved in cell proliferation arrest. In addition, tolerant recipients exhibited significantly greater numbers of circulating potentially regulatory T-cell subsets (CD4+CD25+ T-cells and Vδ1+ T cells) than either non-tolerant patients or healthy individuals. Our data provide novel mechanistic insight on liver allograft operational tolerance, and constitute a first step in the search for a non-invasive diagnostic signature capable of predicting tolerance before undergoing drug weaning.